Author details

Full Name

Thamir M Alshammari

Affiliation

Riyadh Elm University

ORCID

Career Start Year

2014

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37414703	Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data.	Eur Urol	2024
37414703	Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data.	Eur Urol	2024
35915555	Pharmacovigilance regulatory actions by national pharmacovigilance centers in Arab countries following COVID-19 pandemic.	Expert Opin Drug Saf	2023
35915555	Pharmacovigilance regulatory actions by national pharmacovigilance centers in Arab countries following COVID-19 pandemic.	Expert Opin Drug Saf	2023
38028730	Evaluating the impact of alternative phenotype definitions on incidence rates across a global data network.	JAMIA Open	2023
37876736	Interferon-Î»3 rs12979860 can regulate inflammatory cytokines production in pulmonary fibrosis.	Saudi Pharm J	2023
37034358	Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study.	EClinicalMedicine	2023
37464406	The association between drug pricing and drug shortage in Saudi Arabia: a retrospective database analysis.	J Pharm Policy Pract	2023
37328600	Serially Combining Epidemiological Designs Does Not Improve Overall Signal Detection in Vaccine Safety Surveillance.	Drug Saf	2023
36949767	Impact of risk communication on patient's safety during the pandemic.	Ther Adv Drug Saf	2023
36875514	Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.	Ther Adv Drug Saf	2023
36944455	Recording type 2 diabetes mellitus in a standardised central Saudi database: a retrospective validation study.	BMJ Open	2023
37250361	Estimating the potential economic impact of the Wasfaty program on costs of antidiabetic treatment: An initiative for the digital transformation of health.	Saudi Pharm J	2023
37304358	The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration's Adverse Event Reporting System.	Saudi Pharm J	2023
37165105	Saudi Critical Care Society clinical practice guidelines on the prevention of venous thromboembolism in adults with trauma: reviewed for evidence-based integrity and endorsed by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine.	Ann Intensive Care	2023
37876736	Interferon-Î»3 rs12979860 can regulate inflammatory cytokines production in pulmonary fibrosis.	Saudi Pharm J	2023
38028730	Evaluating the impact of alternative phenotype definitions on incidence rates across a global data network.	JAMIA Open	2023
36949767	Impact of risk communication on patient's safety during the pandemic.	Ther Adv Drug Saf	2023
37250361	Estimating the potential economic impact of the Wasfaty program on costs of antidiabetic treatment: An initiative for the digital transformation of health.	Saudi Pharm J	2023
36944455	Recording type 2 diabetes mellitus in a standardised central Saudi database: a retrospective validation study.	BMJ Open	2023
37304358	The use and safety risk of repurposed drugs for COVID-19 patients: lessons learned utilizing the Food and Drug Administration's Adverse Event Reporting System.	Saudi Pharm J	2023
37464406	The association between drug pricing and drug shortage in Saudi Arabia: a retrospective database analysis.	J Pharm Policy Pract	2023
37165105	Saudi Critical Care Society clinical practice guidelines on the prevention of venous thromboembolism in adults with trauma: reviewed for evidence-based integrity and endorsed by the Scandinavian Society of Anaesthesiology and Intensive Care Medicine.	Ann Intensive Care	2023
37034358	Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study.	EClinicalMedicine	2023
37328600	Serially Combining Epidemiological Designs Does Not Improve Overall Signal Detection in Vaccine Safety Surveillance.	Drug Saf	2023
36875514	Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database.	Ther Adv Drug Saf	2023
34764042	The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section.	J Infect Public Health	2022
35769341	Coronavirus disease 2019 in Saudi Arabia: A nationwide real-world characterization study.	Saudi Pharm J	2022
35392566	Current Approaches to Vaccine Safety Using Observational Data: A Rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance-for Vaccines) Study Design.	Front Pharmacol	2022
35653017	Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study.	Drug Saf	2022
35498222	Efficacy and safety of delafloxacin, ceftaroline, ceftobiprole, and tigecycline for the empiric treatment of acute bacterial skin and skin structure infections: A network meta-analysis of randomized controlled trials.	Saudi Pharm J	2022
35873596	Vaccine Safety Surveillance Using Routinely Collected Healthcare Data-An Empirical Evaluation of Epidemiological Designs.	Front Pharmacol	2022
36388318	Health economic burden of COVID-19 in Saudi Arabia.	Front Public Health	2022
36506524	Corrigendum: Vaccine safety surveillance using routinely collected healthcare data-An empirical evaluation of epidemiological designs.	Front Pharmacol	2022
36601511	Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics' impact.	Saudi Pharm J	2022
35049110	The impact of regulatory restrictions on pregabalin use in Saudi Arabia: An interrupted time series analysis.	Pharmacoepidemiol Drug Saf	2022
35188934	Current Situation of Medication Errors in Saudi Arabia: A Nationwide Observational Study.	J Patient Saf	2022
34764042	The Saudi Critical Care Society practice guidelines on the management of COVID-19 in the ICU: Therapy section.	J Infect Public Health	2022
35002372	Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines.	Saudi Pharm J	2022
35345821	Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS.	Clin Epidemiol	2022
35653017	Phenotype Algorithms for the Identification and Characterization of Vaccine-Induced Thrombotic Thrombocytopenia in Real World Data: A Multinational Network Cohort Study.	Drug Saf	2022
35769341	Coronavirus disease 2019 in Saudi Arabia: A nationwide real-world characterization study.	Saudi Pharm J	2022
35345821	Unraveling COVID-19: A Large-Scale Characterization of 4.5 Million COVID-19 Cases Using CHARYBDIS.	Clin Epidemiol	2022
35498222	Efficacy and safety of delafloxacin, ceftaroline, ceftobiprole, and tigecycline for the empiric treatment of acute bacterial skin and skin structure infections: A network meta-analysis of randomized controlled trials.	Saudi Pharm J	2022
35392566	Current Approaches to Vaccine Safety Using Observational Data: A Rationale for the EUMAEUS (Evaluating Use of Methods for Adverse Events Under Surveillance-for Vaccines) Study Design.	Front Pharmacol	2022
36506524	Corrigendum: Vaccine safety surveillance using routinely collected healthcare data-An empirical evaluation of epidemiological designs.	Front Pharmacol	2022
36601511	Vaccine adverse event reporting system (VAERS): Evaluation of 31 years of reports and pandemics' impact.	Saudi Pharm J	2022
35873596	Vaccine Safety Surveillance Using Routinely Collected Healthcare Data-An Empirical Evaluation of Epidemiological Designs.	Front Pharmacol	2022
36388318	Health economic burden of COVID-19 in Saudi Arabia.	Front Public Health	2022
35188934	Current Situation of Medication Errors in Saudi Arabia: A Nationwide Observational Study.	J Patient Saf	2022

1 - 50 of 170

Yong Chen

the Perelman School of Medicine, University of Pennsylvania

Career Start Year 2015

Number of shared co-authors 2

Scott D Nelson

Vanderbilt University Medical Center

Career Start Year 2012

Number of shared co-authors 1

Brittany L Melton

Department of Pharmacy Practice, 2University of Kansas School of Pharmacy

Career Start Year 2012

Number of shared co-authors 1

Phung-Anh Nguyen

Graduate Institute of Data Science, Taipei Medical University

Career Start Year 2012

Number of shared co-authors 11

Nicholas S Downing

Center for Outcomes Research and Evaluation, Yale-New Haven Hospital

Career Start Year 2012

Number of shared co-authors 1

Mei-Sing Ong

Harvard Medical School and Harvard Pilgrim Health Care Institute

Career Start Year 2010

Number of shared co-authors 0

Ameet Sarpatwari

Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital

Career Start Year 2009

Number of shared co-authors 0

Wallis C Y Lau

The University of Hong Kong

Career Start Year 2008

Number of shared co-authors 13

Michael Fralick

University of Toronto

Career Start Year 2007

Number of shared co-authors 0

Hojjat Salmasian

Brigham and Women's Hospital

Career Start Year 2007

Number of shared co-authors 3

Sengwee Toh

Harvard Medical School and Harvard Pilgrim Health Care Institute

Career Start Year 2006

Number of shared co-authors 7

Joshua J Gagne

Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital

Career Start Year 2005

Number of shared co-authors 5

Christine Y Lu

Harvard Medical School and the Harvard Pilgrim Health Care Institute

Career Start Year 2004

Number of shared co-authors 1

Usman Iqbal

College of Public Health, Taipei Medical University

Career Start Year 2004

Number of shared co-authors 11

James M Hoffman

St. Jude Children's Research Hospital Memphis

Career Start Year 2003

Number of shared co-authors 1

Jon Duke

Georgia Tech Research Institute, Georgia Tech College of Computing

Career Start Year 2002

Number of shared co-authors 22

Aaron S Kesselheim

Brigham and Women's Hospital.

Career Start Year 2001

Number of shared co-authors 1

Sandra L Kane-Gill

Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh

Career Start Year 2000

Number of shared co-authors 0

Joseph S Ross

Yale School of Medicine

Career Start Year 1999

Number of shared co-authors 5

Ran D Balicer

Clalit Health Services, Ben Gurion University

Career Start Year 1998

Number of shared co-authors 0

Balthasar L Hug

Center for Primary and Community Care, University of Lucerne

Career Start Year 1998

Number of shared co-authors 1

Emily Beth Devine

University of Washington

Career Start Year 1997

Number of shared co-authors 1

George Caleb Alexander

Institute of General Practice and Family Medicine, University Hospital

Career Start Year 1996

Number of shared co-authors 1

Yu-Chuan Jack Li

Graduate Institute of Biomedical Informatics, Taipei Medical University

Career Start Year 1993

Number of shared co-authors 15

Miriam C J M Sturkenboom

University Medical Center Utrecht

Career Start Year 1991

Number of shared co-authors 12

Paul M Coplan

Perelman School of Medicine, University of Pennsylvania

Career Start Year 1990

Number of shared co-authors 2

Gerald J Dal Pan

Center for Drug Evaluation and Research

Career Start Year 1989

Number of shared co-authors 1

Andy Stergachis

School of Pharmacy, University of Washington

Career Start Year 1980

Number of shared co-authors 0

Dennis W Raisch

The University of New Mexico

Career Start Year 1977

Number of shared co-authors 2

Brian L Strom

Center for Pharmacoepidemiology and Treatment Science, Rutgers University

Career Start Year 1970

Number of shared co-authors 0

row(s) 1 - 30 of 30

Marc A Suchard

University of California los angeles

Co-authored papers 23

Patrick B Ryan

Columbia University Irving Medical Center

Co-authored papers 22

George Hripcsak

Columbia University

Co-authored papers 22

Daniel Prieto-Alhambra

University of Oxford

Co-authored papers 22

Fred Nyberg

University of Gothenburg

Co-authored papers 22

Talita Duarte-Salles

Erasmus University Medical Center

Co-authored papers 21

Daniel R Morales

University of Dundee

Co-authored papers 17

Peter R Rijnbeek

Erasmus University Medical Center

Co-authored papers 17

Lana Y H Lai

The University of Manchester, University of Manchester

Co-authored papers 16

Albert Prats-Uribe

University of Oxford

Co-authored papers 16

Christian Reich

OHDSI Center at The Roux Institute, Northeastern University

Co-authored papers 15

Kristine E Lynch

University of Utah Health

Co-authored papers 15

Michael Matheny

American College of Medical Informatics, Department of Veteran Affairs, Harvard University T H Chan School of Public Health, Massachusetts Institute of Technology, The American Society for Clinical Investigation, University of Kentucky, Vanderbilt University Medical Center, Vanderbilt University Medical School

Co-authored papers 14

Scott L DuVall

University of Utah

Co-authored papers 14

Asieh Golozar

Northeastern University

Co-authored papers 13

Michael E Matheny

Co-authored papers 13

Seng Chan You

Yonsei University College of Medicine

Co-authored papers 13